Hairy Cell Leukemia: Cladribine With Concurrent Rituximab May Improve Outcomes
Rituximab has some single-agent activity in HCL, but there is evidence that it may eliminate MRD when used with cladribine or pentostatin.
All articles by Jonathan Goodman, MPhil
Second Cancers Pose Significant Mortality Risk in Myeloproliferative Neoplasms
Researchers sought to determine whether second cancers associated with MPNs affect a patient’s prognosis, and whether cytoreductive or antiplatelet therapies affect outcomes.
Resequencing Gene Panels May Improve Prognostic Measurements for Chronic Lymphocytic Leukemia
Researchers found that mutated EGR2 and TP53 were significantly associated with worse progression-free survival in patients with chronic lymphocytic leukemia.
Intensive Immunochemotherapy May Yield Positive Outcomes in Burkitt Lymphoma
Researchers assessed data from Australian population-based lymphoma registries to determine the efficacy of intensive immunochemotherapy for Burkitt lymphoma.
Radotinib May Have Similar Efficacy to Imatinib in Chronic Myeloid Leukemia
Researchers reported long-term follow-up results from the phase 3 RERISE study, which assessed the efficacy of radotinib compared with imatinib for CML treatment.
Total Therapy Approach May Improve Transplant Outcomes in Patients With Myeloma
Patients who were enrolled in clinical trials that employed a total therapy protocol had a lower early mortality rate compared with patients not on a total therapy protocol.
Prognostic Factors for Patients Undergoing Autologous Stem Cell Transplant for DLBCL
Researchers assessed potential differences in transplant outcomes in Japan before and after the era that introduced rituximab treatment.
Acalabrutinib With Obinutuzumab May Be Safe, Effective in Chronic Lymphocytic Leukemia
Patients who were treatment-naive had an overall response rate of 95%, while patients with relapsed/refractory disease had an overall response rate of 92%.
Therapeutic Drug Monitoring of Asparaginase in Acute Lymphoblastic Leukemia
Researchers assessed whether adjusted asparaginase dosage helps reduce toxicity while maintaining sufficient asparaginase depletion in children with ALL.
Treosulfan May Offer a New Standard for Prehematopoietic Stem Cell Transplantation Conditioning
Patients receiving treosulfan and fludarabine experienced improved event-free and overall survival compared with patients receiving busulfan and fludarabine.
Next post in Hematologic Cancers
